HIGHLIGHTS
- who: Rowa Bakadlag from the (UNIVERSITY) have published the research: The anti-estrogen receptor drug, tamoxifen, is selectively Lethal to P-glycoprotein-expressing Multidrug resistant tumor cells, in the Journal: (JOURNAL)
- what: In this report the authors show that P-gp-expressing resistant cells (u00ad CHORC5 and MDA-Doxo400) are collaterally sensitive to anti-estrogen tamoxifen or its metabolite (4-hydroxy-tamoxifen). This study shows use of tamoxifen as collateral sensitivity that can preferentially target multidrug resistant cells expressing P-gp at clinically achievable concentrations. The authors show that tamoxifen-induced collateral sensitivity of drug . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.